drugset / Trial / NCT04511871
A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors
Phase 1
Active not recruiting
12 enrolled
Shanghai PerHum Therapeutics Co., Ltd.
Shanghai Zhongshan Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This clinical study is to investigate the safety and tolerability of CCT303-406 CAR modified autologous T cells (CCT303-406) in subjects with relapsed or refractory stage IV metastatic HER2-positive solid tumors.
Timeline
- Start
- 2020-07-09
- Primary completion
- 2024-10-24
- Completion
- 2025-03-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CCT303-406 | Cell therapy | 300000 cells/kg | Intravenous |
| Subject | CCT303-406 | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | CCT303-406 | Cell therapy | 1e+07 cells/kg | Intravenous |